Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-3,4-methylenedioxymethamphetamine
- Development stage
- Unknown
- Lead developer
- MindMed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
R-3,4-methylenedioxymethamphetamine (R-MDMA) is the R(-) enantiomer of the empathogen MDMA. It is being developed by MindMed in collaboration with the Liechti Lab at University Hospital Basel. Unlike the racemic mixture or the S(+) enantiomer, R-MDMA is hypothesized to retain the pro-social and empathogenic effects of MDMA while exhibiting significantly reduced stimulant activity, neurotoxicity, hyperthermia, and abuse liability. The drug acts primarily as a serotonin releaser. While racemic MDMA is in late-stage clinical development for Post-traumatic Stress Disorder (PTSD), R-MDMA is being investigated as a potentially safer alternative for the treatment of social anxiety, social functioning in Autism Spectrum Disorder (ASD), and PTSD.
- Other names
- R-3,4-methylenedioxymethamphetamineR(-)-3,4-methylenedioxymethamphetamineR-enantiomer of MDMA
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))
Beyond the preview
Go deeper on R-3,4-methylenedioxymethamphetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-3,4-methylenedioxymethamphetamine.